<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><description>米内网是中国领先的集医药健康产业研究、医院市场研究、零售市场研究、商业渠道研究、互联网在线医药健康信息服务于一体的综合性专业信息服务平台。目前拥有七项数据分析技术获国家专利，每月收集数据3000多万条，有63个专业数据库为医药健康行业服务。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 14 Apr 2021 17:24:16 +0800</pubDate><image><url>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</url><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>成都倍特发威！将拿下80亿大品种，13款新药、11个首仿来袭，10大“光脚”品种或集采</title><link>https://mp.weixin.qq.com/s/YON-WlyYn6NFnnrl6EjlXQ</link><description></description><content:encoded><![CDATA[成都倍特发威！将拿下80亿大品种，13款新药、11个首仿来袭，10大“光脚”品种或集采]]></content:encoded><pubDate>Wed, 14 Apr 2021 16:06:25 +0800</pubDate></item><item><title>【瞩目】东阳光药1类新药来势汹汹，8款创新药重磅出击</title><link>https://mp.weixin.qq.com/s/Pado0cBmJ9qhcjR3Lu2Fhw</link><description></description><content:encoded><![CDATA[【瞩目】东阳光药1类新药来势汹汹，8款创新药重磅出击]]></content:encoded><pubDate>Wed, 14 Apr 2021 16:06:25 +0800</pubDate></item><item><title>【重磅】$24亿大品种海正将获批，国内销售暴涨170%</title><link>https://mp.weixin.qq.com/s/tFzM5SsXWFdpQdMsQVo07g</link><description></description><content:encoded><![CDATA[【重磅】$24亿大品种海正将获批，国内销售暴涨170%]]></content:encoded><pubDate>Wed, 14 Apr 2021 16:06:25 +0800</pubDate></item><item><title>【关注】每年销售1.3亿盒的降压药，不是外企竟然是他！</title><link>https://mp.weixin.qq.com/s/mTLN1ZmvjYHoG0xCraGfoQ</link><description></description><content:encoded><![CDATA[【关注】每年销售1.3亿盒的降压药，不是外企竟然是他！]]></content:encoded><pubDate>Wed, 14 Apr 2021 16:06:25 +0800</pubDate></item><item><title>豪森、东阳光药、倍特……20个新品冲击市场！龙头喜提1类新药，国采品种暴涨六成</title><link>https://mp.weixin.qq.com/s/a93NoPETkg47e_nT8LsIyA</link><description></description><content:encoded><![CDATA[豪森、东阳光药、倍特……20个新品冲击市场！龙头喜提1类新药，国采品种暴涨六成]]></content:encoded><pubDate>Tue, 13 Apr 2021 16:17:36 +0800</pubDate></item><item><title>【重磅】科伦1类新药大爆发，本月3个重磅密集来袭</title><link>https://mp.weixin.qq.com/s/6lTCj_DcctDWpgCNOVAwVA</link><description></description><content:encoded><![CDATA[【重磅】科伦1类新药大爆发，本月3个重磅密集来袭]]></content:encoded><pubDate>Tue, 13 Apr 2021 16:17:36 +0800</pubDate></item><item><title>【火爆】国内药企猛攻$120亿抗肿瘤药，扬子江再下一城</title><link>https://mp.weixin.qq.com/s/QphQ_cMWy4hU3doKmrxBAw</link><description></description><content:encoded><![CDATA[【火爆】国内药企猛攻$120亿抗肿瘤药，扬子江再下一城]]></content:encoded><pubDate>Tue, 13 Apr 2021 16:17:36 +0800</pubDate></item><item><title>【热议】华海将拿下重磅首仿，原研药企独占市场破局</title><link>https://mp.weixin.qq.com/s/9I1SN42950uLBlh5AhQXbg</link><description></description><content:encoded><![CDATA[【热议】华海将拿下重磅首仿，原研药企独占市场破局]]></content:encoded><pubDate>Tue, 13 Apr 2021 16:17:36 +0800</pubDate></item><item><title>呼吸系统中成药排位生变！扬子江、以岭……14个独家产品“抢占”TOP20，3大新药发起冲击</title><link>https://mp.weixin.qq.com/s/v9F2vEQ664bqJwJY7rXnbw</link><description></description><content:encoded><![CDATA[呼吸系统中成药排位生变！扬子江、以岭……14个独家产品“抢占”TOP20，3大新药发起冲击]]></content:encoded><pubDate>Mon, 12 Apr 2021 16:30:39 +0800</pubDate></item><item><title>【瞩目】$20亿口服降糖药！正大天晴抢首仿</title><link>https://mp.weixin.qq.com/s/oIaMfVF6LEqXc1hg_rMVYw</link><description></description><content:encoded><![CDATA[【瞩目】$20亿口服降糖药！正大天晴抢首仿]]></content:encoded><pubDate>Mon, 12 Apr 2021 16:30:39 +0800</pubDate></item><item><title>【关注】齐鲁将拿下$14亿大品种！原研药再受冲击</title><link>https://mp.weixin.qq.com/s/IG8hrY9ed-pnrO4QpgHGGQ</link><description></description><content:encoded><![CDATA[【关注】齐鲁将拿下$14亿大品种！原研药再受冲击]]></content:encoded><pubDate>Mon, 12 Apr 2021 16:30:39 +0800</pubDate></item><item><title>【PCPI论坛】临床大咖齐聚苏州，共创新药研发良好生态！</title><link>https://mp.weixin.qq.com/s/SNJNBt32rPfV6c9IZzDzGQ</link><description></description><content:encoded><![CDATA[【PCPI论坛】临床大咖齐聚苏州，共创新药研发良好生态！]]></content:encoded><pubDate>Mon, 12 Apr 2021 16:30:39 +0800</pubDate></item><item><title>知名药企遭巨额索赔，6位医药大佬身家超$100亿！2000多个常用药医院不卖了……</title><link>https://mp.weixin.qq.com/s/fCQY1B5Qo7MEQiHrIYavTw</link><description></description><content:encoded><![CDATA[知名药企遭巨额索赔，6位医药大佬身家超$100亿！2000多个常用药医院不卖了……]]></content:encoded><pubDate>Sun, 11 Apr 2021 07:59:45 +0800</pubDate></item><item><title>众生睿创：深入NASH和甲流新药，两大未被满足的临床领域</title><link>https://mp.weixin.qq.com/s/brsdWz9gvB52EqSR7SUP3g</link><description></description><content:encoded><![CDATA[众生睿创：深入NASH和甲流新药，两大未被满足的临床领域]]></content:encoded><pubDate>Sun, 11 Apr 2021 07:59:45 +0800</pubDate></item><item><title>46个独家中成药大卖100亿！2大品种逆势大涨超50%，四川药企产品遭“腰斩”</title><link>https://mp.weixin.qq.com/s/cMt9OET1Y6Xy_NOywrsmog</link><description></description><content:encoded><![CDATA[46个独家中成药大卖100亿！2大品种逆势大涨超50%，四川药企产品遭“腰斩”]]></content:encoded><pubDate>Sat, 10 Apr 2021 08:00:23 +0800</pubDate></item><item><title>【点赞】大突破！百亿乙肝市场将迎来首个中国原创创新药</title><link>https://mp.weixin.qq.com/s/cJRxQiBjsDepRFah4-hZQA</link><description></description><content:encoded><![CDATA[【点赞】大突破！百亿乙肝市场将迎来首个中国原创创新药]]></content:encoded><pubDate>Sat, 10 Apr 2021 08:00:23 +0800</pubDate></item><item><title>米内网十周年发展历程</title><link>https://mp.weixin.qq.com/s/5x9TbEnc2k_84eq_MtqCfw</link><description></description><content:encoded><![CDATA[米内网十周年发展历程]]></content:encoded><pubDate>Fri, 09 Apr 2021 10:24:09 +0800</pubDate></item><item><title>这家药企厉害！25款创新药、19个新品发力，研发投入5年翻三倍，自研+引进丰富管线</title><link>https://mp.weixin.qq.com/s/xU0fBFG6eIMYGvpQgB5h6Q</link><description></description><content:encoded><![CDATA[这家药企厉害！25款创新药、19个新品发力，研发投入5年翻三倍，自研+引进丰富管线]]></content:encoded><pubDate>Thu, 08 Apr 2021 16:27:58 +0800</pubDate></item><item><title>【瞩目】科伦1类新药来袭，20亿注射剂首家过评，4大重磅品种将获批</title><link>https://mp.weixin.qq.com/s/TASFdS-CxBKOmJOF83H0ww</link><description></description><content:encoded><![CDATA[【瞩目】科伦1类新药来袭，20亿注射剂首家过评，4大重磅品种将获批]]></content:encoded><pubDate>Thu, 08 Apr 2021 16:27:58 +0800</pubDate></item><item><title>【市场】苑东发威！$17亿抗凝药将拿下</title><link>https://mp.weixin.qq.com/s/HcssddpfeYuHq2kYOmBEMw</link><description></description><content:encoded><![CDATA[【市场】苑东发威！$17亿抗凝药将拿下]]></content:encoded><pubDate>Thu, 08 Apr 2021 16:27:58 +0800</pubDate></item></channel></rss>